Importance Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early
clinical development for cardiovascular prevention. Studying whether these agents will
reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs
would require large outcome trials. Human genetics studies can help prioritize or deprioritize
these resource-demanding endeavors. Objective To investigate the independent and
combined associations of genetically determined differences in LPL-mediated lipolysis and …